Evidence map›Paper›PMID 41277442›Full record

ArticleJournal of medicinal chemistry2025

Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase.

Paul R Palme, Shipra Grover, Rana Abdelaziz, Lea Mann, Andreas M Kany, Lina Ouologuem, Karin Bartel, Lindsay Sonnenkalb, Norbert Reiling, Anna K H Hirsch and 4 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Crystal structure of theActa crystallographica. Section E, Crystallographic communications · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paul R PalmePharmaceutical Chemistry, Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Shipra GroverDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.ORCID 0000-0001-7094-6879
Rana AbdelazizMolecular Medicine Program, The Hospital for Sick Children, Toronto, ON M5G1H3, Canada.
Lea MannPharmaceutical Chemistry, Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Andreas M KanyHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Saarbrücken 66123, Germany.
Lina OuologuemDepartment of Pharmacy, Faculty of Chemistry and Pharmacy, Ludwig Maximilian University of Munich, Munich 81377, Germany.
Karin BartelDepartment of Pharmacy, Faculty of Chemistry and Pharmacy, Ludwig Maximilian University of Munich, Munich 81377, Germany.ORCID 0000-0002-6634-547X
Lindsay SonnenkalbMolecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center, Borstel 23845, Germany.
Norbert ReilingMicrobial Interface Biology, Research Center Borstel, Leibniz Lung Center, Borstel 23845, Germany.ORCID 0000-0001-6673-4291
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Saarbrücken 66123, Germany.ORCID 0000-0001-8734-4663
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.ORCID 0000-0002-4445-7219
John L RubinsteinMolecular Medicine Program, The Hospital for Sick Children, Toronto, ON M5G1H3, Canada.ORCID 0000-0003-0566-2209
Peter ImmingPharmaceutical Chemistry, Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Adrian RichterPharmaceutical Chemistry, Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.ORCID 0000-0002-0062-7896

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amides of squaric acid are new drug candidates with activity against mycobacteria. Like the approved drug bedaquiline, these compounds achieve efficacy by inhibiting mycobacterial ATP synthase. However, squaramides have a different binding site than bedaquiline and possess the potential to inhibit bedaquiline-resistant strains. We developed an optimized synthesis for monoamino-substituted squaric acid analogues. Guided by an atomic model of a squaramide compound bound to its target, we synthesized 31 new monoamino/diamino-substituted squaric acid derivates. The efficacy of these compounds was determined in whole-cell assays against

Indexed as

Antitubercular AgentsATP Synthetase ComplexesCyclobutanesDrug DesignEnzyme InhibitorsMycobacterium tuberculosisAnimalsHumansMicrobial Sensitivity TestsMycobacterium aviumMycobacterium smegmatisQuinineStructure-Activity RelationshipAntitubercular AgentsATP Synthetase ComplexesCyclobutanesEnzyme InhibitorsQuininesquaramide

Identifiers

PMID41277442
PMCPMC12703743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.